- The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomains.
The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomains.
Oncotarget (2017-12-22)
Mohammad Alzrigat, Alba Atienza Párraga, Muntasir Mamun Majumder, Anqi Ma, Jian Jin, Anders Österborg, Hareth Nahi, Kenneth Nilsson, Caroline A Heckman, Fredrik Öberg, Antonia Kalushkova, Helena Jernberg-Wiklund
PMID29262596
ZUSAMMENFASSUNG
Multiple myeloma (MM) is a tumor of plasmablasts/plasma cells (PCs) characterized by the expansion of malignant PCs with complex genetic aberrations in the bone marrow (BM). Recent reports, by us and others, have highlighted the polycomb group (PcG) proteins as potential targets for therapy in MM. The PcG protein BMI-1 of the polycomb repressive complex 1 (PRC1) has been reported to be overexpressed and to possess oncogenic functions in MM. Herein, we report on the anti-myeloma effects of the BMI-1 inhibitor PTC-209 and demonstrate that PTC-209 is a potent anti-myeloma agent
MATERIALIEN